Loading…
To provide for a limitation on availability of funds for Executive Office of the President, Office of National Drug Control Policy, Salaries and Expenses for fiscal year 2024.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · second_quarter · Medicare/Medicaid
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Client expense: $640,000 · Firm income: Not reported
Referred to the House Committee on Oversight and Accountability.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Client expense: $600,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| FL |
| Matthew M. Rosendale, Sr. | Republican | MT |